This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).

Inclusion Criteria:

• Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC) during the study.

Exclusion Criteria

• Workers with positive Covid-19 RT-PCR prior to the start of the study
• Those that did not take the first dose of Ivermectin the first week at the start of the study
• Those that did not complied with at least 2 out of 4 weekly doses
• Those that had greater than 14 days difference in days between two intakes Ivermectin

Workers who was part of Ivermectin prophylaxis program and signed the informed consent at CMPC and CMBO in Dominican Republic was analyzed and included in the intervention group. Those who didn't participate in the prophylaxis program but were on active duty during the 4 weeks of the study were included in the control group.

Workers excluded from Ivermectin prophylaxis program was:

• Pregnant or suspected pregnant women
• Women breastfeeding
• Patients receiving coumarin anticoagulants
• Those allergic to Ivermectin